Patent Application
20230404799
Optic neuropathies, such as glaucomatous optic neuropathy, ischemic optic neuropathies, autoimmune disease, optic disc drusen, and toxic/metabolic optic neuropathies, are vision threatening disorders affecting millions of Americans. Though some optic neuropathies have good visual prognosis in the near term, most cause permanent and sometimes even catastrophic vision loss. This is because as retinal ganglion cell (RGC) axons are lost, they do not spontaneously regenerate, and at some later point, the RGCs die and are not replaced. Thus, new clinical strategies to slow disease progression or promote RGC survival and/or axon growth are needed.
Targeted delivery of therapeutics may be useful in promoting organized axon regeneration because it can (i) reach difficult-to-reach diseased tissues, and (ii) establish spatial cues. In some diseases, such as glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), the optic nerve head (ONH) is the likely site of injury and targeting the ONH could be used to counteract injury signals that dampen axon regeneration. However, current approaches have failed to demonstrate reliable access to the ONH. Intravitreal injections, intraorbital optic nerve injections, and systemic administration are the current state of the art in dosing the ONH. Intravitreal injections in small animals have demonstrated uptake by the retinal nerve fiber layer. However, a concentration gradient, if it is even established, directed toward the vitreous is unlikely to be physiologic and is not expected to optimally promote axon regeneration down the optic nerve. Furthermore, intravitreal injections deliver drugs to the retinal ganglion cell soma, and less to the RGC axons in the ONH. Intraorbital optic nerve injections have also been used to target the optic nerve, but this is expected to localize drugs behind the lamina cribrosa and it is unclear how such signaling would reach axons or promote regeneration.
Provided are methods of delivering a therapeutic agent to the optic nerve head (ONH) of a subject. The methods comprise creating a sclerostomy posterior to the limbus of the subject and feeding a catheter with a distal needle tip tangentially into the sclerostomy. The methods further comprise tunneling the catheter through the suprachoroidal space (SCS) toward the ONH, and disposing the needle tip adjacent, or into, the ONH. The methods further comprise injecting the therapeutic agent adjacent or into the ONH. The methods find use in a variety of contexts, including but not limited to, treating an ONH-associated condition in a subject in need thereof. Examples of such conditions include, but are not limited to, optic neuropathies such as glaucoma, non-arteritic anterior ischemic optic neuropathy (NAION), and the like. Devices and kits that find use in practicing the methods of the present disclosure are also provided.
Before the methods, devices and kits of the present disclosure are described in greater detail, it is to be understood that the methods, devices and kits are not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the methods, devices and kits will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the methods, devices and kits. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the methods, devices and kits, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the methods, devices and kits.
Certain ranges are presented herein with numerical values being preceded by the term “about.” The term “about” is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods, devices and kits belong. Although any methods, devices and kits similar or equivalent to those described herein can also be used in the practice or testing of the methods, devices and kits, representative illustrative methods, devices and kits are now described.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the materials and/or methods in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present methods, devices and kits are not entitled to antedate such publication, as the date of publication provided may be different from the actual publication date which may need to be independently confirmed.
It is noted that, as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
It is appreciated that certain features of the methods, devices and kits, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the methods, devices and kits, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments are specifically embraced by the present disclosure and are disclosed herein just as if each and every combination was individually and explicitly disclosed, to the extent that such combinations embrace operable processes and/or compositions. In addition, all sub-combinations listed in the embodiments describing such variables are also specifically embraced by the present methods, devices and kits and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present methods. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
Aspects of the present disclosure include methods of delivering therapeutic agents to the optic nerve head (ONH) of a subject. In some embodiments, the methods comprise creating a sclerostomy posterior to the limbus of the subject, feeding a catheter with a distal needle tip tangentially into the sclerostomy, and tunneling the catheter through the suprachoroidal space (SCS) toward the ONH. Such methods further comprise disposing the needle tip adjacent, or into, the ONH, and injecting the therapeutic agent adjacent or into the ONH. The methods find use in treating ONH-associated conditions, non-limiting examples of which include optic neuropathies.
There are currently no satisfactory or FDA-approved approaches for delivering therapeutic agents to the ONH. Existing approaches are illustrated in
A schematic illustration of a method for delivering therapeutic agents to the optic nerve head according to embodiments of the present disclosure (sometimes referred to herein as SupraChoroidal-to-Optic-NErve (SCONE) injection) is shown in
The sclerostomy may be created at any suitable location. In certain embodiments, the sclerostomy is created from 0.5 to 7 mm posterior to the limbus, e.g., from 1 to 6 mm, 2 to 5 mm, or 3 to 4 mm posterior to the limbus.
In some instances, the sclerostomy is created by inserting a hollow microneedle through the sclera. The hollow microneedle may be made of any suitable material. According to some embodiments, the hollow microneedle is made of a metal, e.g., stainless steel (e.g., an alloy of iron with carbon, silicon, manganese and chromium). In certain embodiments, the hollow microneedle is made of ceramic, tungsten carbide, titanium, polyetheretherketone (PEEK), nitinol, or any combination thereof.
The dimensions of the hollow microneedle may vary. According to some embodiments, the length of the hollow microneedle is from 300 μm to 1.7 mm, from 400 μm to 1.6 mm, from 500 μm to 1.5 mm, from 750 μm to 1.4 mm, from 800 μm to 1.2 mm, or from 900 μm to 1.1 mm, e.g., about 1 mm. In some instances, the inner diameter of the hollow microneedle is from 100 to 500 μm, from 200 to 400 μm, or from 250 to 350 μm, e.g., about 300 μm.
In certain embodiments, for sclerostomy creation, the microneedle insertion angle (that is, the angle relative to the surface of the sclera at which the microneedle is inserted through the sclera) is 45 to 65 degrees, such as 48 to 62 degrees, 50 to 60 degrees, or from 52 to 58 degrees, e.g., about 55 to 57 degrees.
According to some embodiments, the hollow microneedle is mounted on a distal face (e.g., of a base plate) of a device used to perform the method, and wherein the angle of the microneedle is 45 to 65 degrees, such as 48 to 62 degrees, 50 to 60 degrees, or from 52 to 58 degrees, e.g., about 55 to 57 degrees, relative to the face of the base plate such that the microneedle inserts through the sclera at the angle.
In certain embodiments, when a hollow microneedle is employed to create the sclerostomy, the feeding comprises passing the catheter through the lumen of the hollow microneedle. In some instances, when a hollow microneedle is employed to create the sclerostomy, a viscoelastic agent is injected into the SCS while the hollow microneedle is still inserted through the sclera. See, e.g.,
The methods of the present disclosure utilize a catheter. The dimensions of the catheter may vary. In certain embodiments, the outer diameter of the catheter is from 100 to 400 μm, e.g., from 150 to 350 μm, from 200 to 300 μm, or from 225 to 275 μm. The inner diameter of the catheter may similarly vary and in some instances is from 50 to 250 μm, from 75 to 225 μm, or from 100 to 200 μm, e.g., from 125 to 175 μm.
The catheter may be made of any suitable material. In certain embodiments, the catheter is made of plastic. According to some embodiments, the catheter is made of silicone, polyurethane (PU), polyethylene (PE), polyvinylchloride (PVC), PTFE, latex, Teflon, rubber (e.g., red rubber), nylon, or any combination thereof. According to some embodiments, the catheter is made of a metal, e.g., stainless steel (e.g., an alloy of iron with carbon, silicon, manganese and chromium). In certain embodiments, the needle tip is made of ceramic, tungsten carbide, titanium, polyetheretherketone (PEEK), nitinol, or any combination thereof.
According to some embodiments, the feeding comprises feeding the catheter tangential to the sclera at an angle of from 20 to 40 degrees, or from 25 to 35 degrees, e.g., about 30 degrees.
In some instances, the catheter comprises a needle tip and the needle tip is disposed adjacent, or into, the ONH. In other embodiments, the catheter does not comprise a needle tip. For example, in some embodiments, when the therapeutic agent is to be injected adjacent (rather than into) the ONH, the catheter may or may not comprise a distal needle tip.
When the catheter comprises a distal needle tip, the needle tip bevel angle is from 25 to degrees, from 35 to 50 degrees. The needle tip may be made of any suitable material. According to some embodiments, the needle tip is made of a metal, e.g., stainless steel (e.g., an alloy of iron with carbon, silicon, manganese and chromium). In certain embodiments, the needle tip is made of ceramic, tungsten carbide, titanium, polyetheretherketone (PEEK), nitinol, or any combination thereof.
In certain embodiments, during the feeding and tunneling steps, the catheter (e.g., including a distal needle tip) is covered with a sheath. The catheter is typically slidable relative to the sheath through the lumen of the sheath. In some instances, during the disposing and/or injecting step, the distal tip (e.g., distal needle tip) of the catheter is unsheathed, e.g., by advancing the catheter distally relative to the sheath, or by retracting the sheath proximally relative to the catheter.
The sheath may be made of any suitable material, e.g., plastic, silicone, polyimide, polyurethane (PU), polyethylene (PE), polyvinylchloride (PVC), PTFE, latex, Teflon, rubber (e.g., red rubber), nylon, combinations thereof, or the like. When a sheath is employed, in some instances, the distal tip of the sheath comprises a light (e.g., a flashing light), and the method comprises using the light to visualize the tip of the sheath during the tunneling. According to some embodiments, whether or not a sheath is employed, the tip of the catheter may comprise a light (e.g., a flashing light), and the method comprises using the light to visualize the tip of the catheter during the tunneling.
As summarized above, the methods comprise disposing the distal end of the catheter (e.g., the distal needle tip) adjacent, or into, the ONH. Thus, in some instances, the distal end is disposed adjacent the ONH. When the distal end is disposed adjacent the ONH, the distal end may be disposed in the peripapillary SCS, and the therapeutic agent is injected/deposited into the peripapillary SCS. See, e.g.,
The methods may be employed to deliver a wide variety of therapeutic agents in various dosage forms to the ONH of the subject. In some embodiments, the therapeutic agent is injected as a liquid formulation. When the therapeutic agent is injected as a liquid formulation, in some instances, from 0.1 to 10 μL, such as from 1 to 8 μL (e.g., from 1 to 5 μL), or from 3 to 6 μL, of the therapeutic agent is injected adjacent or into the ONH.
Non-liquid dosage forms of therapeutic agents may also be employed. For example, in certain embodiments, the therapeutic agent is deposited as a solid implant that elutes the therapeutic agent. In certain embodiments, the solid implant is a polymer-based implant. Non-limiting examples of polymer-based drug-eluting implants that may be employed include polylactic-co-glycolic acid (PLGA), poly e-caprolactone (PCL), poly-L-lactic acid (PLLA), silicone, urethane, or acrylate implants. In some instances, the methods employ a mesoporous silica implant as the solid drug-eluting implant. According to some embodiments, the therapeutic agent is deposited as microparticles that elute the therapeutic agent. Non-limiting examples of such microparticles include drug-eluting microspheres, e.g., polyethylene glycol (PEG) drug-eluting microspheres.
The identity of the therapeutic agent will vary depending upon the condition of the subject to be treated. In some embodiments, the subject has an optic neuropathy. Non-limiting examples of optic neuropathies include glaucomatous optic neuropathy, ischemic optic neuropathy, autoimmune disease-associated optic neuropathy, optic disc drusen, toxic optic neuropathy, metabolic optic neuropathy, compressive optic neuropathy, Infiltrative optic neuropathy, traumatic optic neuropathy, and optic neuritis. According to some embodiments, the subject has glaucoma. In certain embodiments, the subject has non-arteritic anterior ischemic optic neuropathy (NAION).
In some instances, the therapeutic agent is a neurotrophic factor. A non-limiting example of a neurotrophic factor that may be delivered to the ONH of the subject is ciliary neurotrophic factor (CNTF).
As will be appreciated with the benefit of the present disclosure, the methods may be employed to treat an ONH-associated condition, including but not limited to, any of the optic neuropathies, glaucoma, and the like, described elsewhere herein. By “treat” or “treatment” is meant at least an amelioration of one or more symptoms associated with the condition of the subject (e.g., optic neuropathy, glaucoma, or the like), where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g., symptom, associated with the condition being treated. As such, treatment also includes situations where the condition (e.g., optic neuropathy, such as glaucoma, or the like), or at least one or more symptoms associated therewith, are completely inhibited, e.g., prevented from happening, or stopped, e.g., terminated, such that the subject no longer suffers from the condition, or at least the symptoms that characterize the condition.
The therapeutic agent may be administered (e.g., in a pharmaceutical composition) in a therapeutically effective amount. By “therapeutically effective amount” is meant a dosage sufficient to produce a desired result, e.g., an amount sufficient to effect beneficial or desired therapeutic (including preventative) results, such as a reduction in a symptom of an optic neuropathy, such as glaucoma, or the like, as compared to a control. An effective amount can be administered in one or more administrations.
Also provided by the present disclosure are devices and kits, which devices and kits find use in practicing the methods of the present disclosure.
In some embodiments, a device of the present disclosure comprises a body and a hollow microneedle extending distally from the body, where the hollow microneedle is adapted to create a sclerostomy posterior to the limbus of a human subject. Such a device further comprises a catheter with a distal needle tip, where the catheter is slidable relative to and distally through the hollow microneedle, and where the catheter is sized and adapted to be tunneled through the suprachoroidal space (SCS) from the sclerostomy to the ONH of the subject. Such a device further comprises an actuator operable to actuate the catheter relative to the hollow microneedle and drive the catheter to the ONH of the subject, and a valve assembly operable to provide a fluid coupling between a fluid source and the catheter. Features of the hollow microneedle, catheter, etc. may be as described in the Methods section above and are not reiterated herein for purposes of brevity.
In certain embodiments, the microneedle extends distally from the body at an angle of 50 to 60 degrees such that the microneedle inserts through the sclera at the angle. In some instances, the microneedle is mounted on a distal face of the device, where the microneedle extends at an angle of 50 to 60 degrees from and relative to the distal face. According to some embodiments, wherein the microneedle is mounted on a distal face of the device, wherein the microneedle extends substantially perpendicular from and relative to the distal face, and wherein the distal face comprises an angle of 50 to 60 degrees relative to the body of the device. See, e.g.,
In some instances, the device comprises a reservoir operably coupled to the hollow microneedle. As used herein, “operably coupled” means that the two elements are in a functional relationship with each other. In certain embodiments, the device is adapted to inject a substance (e.g., a viscoelastic agent as described elsewhere herein) from the reservoir through the hollow microneedle into the SCS of the subject.
A non-limiting example of a device of the present disclosure is illustrated in
Shown in
The device may implement a variety of different types of catheters, non-limiting examples of which are shown in
Aspects of the present disclosure further include kits. In some instances, a kit of the present disclosure includes one or any combination of any (e.g., each) of the components of the devices of the present disclosure, and instructions for using the components for performing any of the methods of the present disclosure. In certain embodiments, a kit includes any of the devices of the present disclosure, and instructions for using the components for performing any of the methods of the present disclosure.
The instructions included in the kits may be recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or sub-packaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g., portable flash drive, DVD, CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, the means for obtaining the instructions is recorded on a suitable substrate.
Notwithstanding the appended claims, the present disclosure is also defined by the following embodiments:
Described herein is an injection technique which may be implemented to deliver therapeutic agents to the optic nerve head (ONH) via the suprachoroidal space (SCS). An embodiment of this approach, sometimes referred to herein as SupraChoroidal-to-Optic-NErve (SCONE) tunneling injection, is schematically illustrated in
Shown in
Shown in
Of these techniques, (A) and (B) were able to inject into the intraorbital segment of the optic nerve, but did not distribute to the ONH. Injection techniques (C) and (E) were able to deliver to the ONH but damaged the lamina cribrosa (LC). Injection technique (D) did not deliver to the ONH. Surprisingly, out of the tested injection techniques, only technique (F) (SCONE) was able to deliver to the ONH without significant damage to the lamina cribrosa.
Described in this example is the assessment of microneedle length and microneedle insertion angle on sclerostomy creation.
The insertion angle was varied from 90 degrees (perpendicular to sclera) to 56 degrees. The length of the microneedle was varied from 0 mm to 1.6 mm. After applying the microneedle to the sclera at each needle length and insertion angle, a catheter was extended through the lumen of the microneedle. The disposition of the catheter tip was recorded as outside the eye (microneedle had not created a successful sclerostomy), within the suprachoroidal space (microneedle had created a successful sclerostomy without penetrating through choroid and retina), and through retina (microneedle had penetrated through sclera, choroid, and retina). Five replicates were performed for each condition to determine the optimal length of microneedle and insertion angle to enter the suprachoroidal space. A microneedle length of 800 to 1200 μm and insertion angle of 56 degrees was chosen due to reliable access into the suprachoroidal space. Results are summarized in
Shown in this example is successful delivery of India ink to the ONH of a rabbit eye via SCONE injection. The rabbit optic nerve head is visible pre-injection on fundus camera and optical coherence tomographic (OCT) images of the optic nerve head (
Assessed in this example was whether SCONE injection disrupts connectivity between the eye and brain. Visual evoked potentials were performed on the SCONE-treated eye and its fellow untreated eye 3 weeks after SCONE injection. Representative VEP recordings from one animal are shown in
Accordingly, the preceding merely illustrates the principles of the present disclosure. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein.
This application claims the benefit of U.S. Provisional Patent Application No. 63/348,162, filed Jun. 2, 2022, which application is incorporated herein by reference in its entirety.
This invention was made with Government support under contract EY033407 awarded by the National Institutes of Health. The Government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 63348162 | Jun 2022 | US |
